489 related articles for article (PubMed ID: 24837142)
1. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines.
Stephan H; Boeloeni R; Eggert A; Bornfeld N; Schueler A
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):3158-63. PubMed ID: 18579764
[TBL] [Abstract][Full Text] [Related]
3. Non-Photoinduced Biological Properties of Verteporfin.
Gibault F; Corvaisier M; Bailly F; Huet G; Melnyk P; Cotelle P
Curr Med Chem; 2016; 23(11):1171-84. PubMed ID: 26980565
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin inhibits growth of human glioma in vitro without light activation.
Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
[TBL] [Abstract][Full Text] [Related]
5. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
Wei C; Li X
Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
[TBL] [Abstract][Full Text] [Related]
6. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
Wei C; Li X
BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
[TBL] [Abstract][Full Text] [Related]
7. Verteporfin regulates corneal neovascularization through inhibition of YAP protein activation.
Lin L; Zheng Y; Li Q; Sun Y; Huang Y; Liang L; Xu L; Zhao YE
Exp Eye Res; 2024 Jan; 238():109747. PubMed ID: 38072353
[TBL] [Abstract][Full Text] [Related]
8. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
[TBL] [Abstract][Full Text] [Related]
9. Rabbit model of ocular indirect photodynamic therapy using a retinoblastoma xenograft.
Kim JW; Jacobsen B; Zolfaghari E; Ferrario A; Chevez-Barrios P; Berry JL; Lee DK; Rico G; Madi I; Rao N; Stachelek K; Wang LC; Gomer C
Graefes Arch Clin Exp Ophthalmol; 2017 Dec; 255(12):2363-2373. PubMed ID: 28971251
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of photodynamic therapy in three new xenograft models of human retinoblastoma.
Aerts I; Leuraud P; Blais J; Pouliquen AL; Maillard P; Houdayer C; Couturier J; Sastre-Garau X; Grierson D; Doz F; Poupon MF
Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):275-83. PubMed ID: 21112551
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
Dong L; Lin F; Wu W; Liu Y; Huang W
Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
[TBL] [Abstract][Full Text] [Related]
12. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
[TBL] [Abstract][Full Text] [Related]
13. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
14. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
[TBL] [Abstract][Full Text] [Related]
15. Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment.
Song M; Zhu L; Zhang L; Ge X; Cao J; Teng Y; Tian R
Mol Pharm; 2024 May; 21(5):2340-2350. PubMed ID: 38546166
[TBL] [Abstract][Full Text] [Related]
16. The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor.
Wei C; Li X
Front Pharmacol; 2020; 11():557429. PubMed ID: 33178014
[TBL] [Abstract][Full Text] [Related]
17. Verteporfin without light stimulation inhibits YAP activation in trabecular meshwork cells: Implications for glaucoma treatment.
Chen WS; Cao Z; Krishnan C; Panjwani N
Biochem Biophys Res Commun; 2015 Oct; 466(2):221-5. PubMed ID: 26361148
[TBL] [Abstract][Full Text] [Related]
18. The killing effect of photodynamic therapy using benzoporphyrin derivative on retinoblastoma cell line in vitro.
Jin C; Wu Z; Li Y; Li Y; Chen H; North J
Yan Ke Xue Bao; 1999 Mar; 15(1):1-6. PubMed ID: 12579652
[TBL] [Abstract][Full Text] [Related]
19. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
[TBL] [Abstract][Full Text] [Related]
20. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
